You are here: Industry Insights > SGLT2

News List

FDA approves label update to sodium glucose co-transporter-2 (SGLT2) inhibitors europeanpharmaceuticalreview
March 19, 2020
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes drugs
January 14, 2020
Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study published online Jan. 14 in the A
AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF pharmaceutical-business-review
January 09, 2020
AstraZeneca’s Farxiga (dapagliflozin) has been granted priority review from the US Food and Drug Administration (FDA) for a certain population of patients with heart failure.
SGLT2 Inhibitors Linked to Lower Risk for Heart Failure drugs
September 23, 2019
Use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes is associated with a reduced risk for heart failure ...
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors drugs
July 25, 2019
Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetic ketoacidosis (DKA) may occur after surgery even in patients...
Canagliflozin may not be associated with fracture risk in diabetes patients europeanpharmaceuticalreview
January 03, 2019
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes…